[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5imrR41hOXX0cxapqWGHXsK6m6oJ8masbxZ29PpBsO0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"Nationwide Children's Hospital",[4],229,false,49,20,34833,41,146,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"High Grade Glioma",9,{"name":18,"count":19},"Burns",7,{"name":21,"count":19},"Diffuse Intrinsic Pontine Glioma",{"name":23,"count":19},"Surgery",{"name":25,"count":26},"Low Back Pain",5,{"name":28,"count":26},"Acute Pain",{"name":30,"count":31},"Procedural Pain",4,{"name":33,"count":31},"Pain",[35,40,45,50,55,60,65,70,75,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03605550","A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma","2024-03-01","PTC596",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT02378428","MIBG Therapy for Patients With MIBG Avid Tumors","2025-12-31","MIBG",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05547165","Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants","2026-02-28","Responsive Management Intervention",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05135975","A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors","2026-07","Cabozantinib",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04467671","Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts","2026-08","Tissue Engineered Vascular Grafts",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04722029","Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections","2026-10-01","Adenovirus Specific T lymphocytes",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04211675","NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab","2026-12","Natural Killer Cells",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04655404","A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion","2026-12-01","Larotrectinib",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT05634369","A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","GEM\u002FDOX + TGFBi expanded NK cells",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05503134","Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed\u002FRefractory AML","2027-02","Universal Donor Natural Killer Cells",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,126,144,162,180,198,216,243,303,329,355,375,393,411,440,458,476,494,512,547,577,602,625,643,661,693,715,736,761,783,808,829,850,880,909,927,945,963,987,1013,1034,1059,1114,1149,1175,1199,1237,1279,1309,1336,1367,1390,1417,1443,1468,1486,1511,1534,1558,1582,1607,1634,1652,1670,1696,1714,1744,1766,1788,1814,1832,1850,1878,1903,1921,1939,1957,1975,1993,2011,2029,2047,2071,2089,2107,2134,2152,2170,2188,2206,2232,2250,2277,2301,2319,2342,2366,2384,2407,2432,2457,2475,2498,2522,2546,2574,2592,2632,2659,2685,2712,2734,2758,2782,2804,2822,2849,2867,2889,2913,2938,2956],{"intervention":93,"totalTrials":94,"cells":95},"Bridging Chemotherapy",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":122,"NA":124},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT07291102","Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","NOT_YET_RECRUITING",[88],"2034-10","2038-10","2026-07-01",96,[115],"Medulloblastoma",[93,117,118,119,120,121],"Induction Cycles A1-A3","Induction Cycles A4-5","Consolidation Cycle A6","HIT-SKK Chemotherapy Cycles B1-3","Modified HIT-SKK Cycle B4-5",{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":98},[],{"intervention":117,"totalTrials":94,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":140,"NA":142},{"trials":129,"activeCount":98},[],{"trials":131,"activeCount":98},[],{"trials":133,"activeCount":98},[],{"trials":135,"activeCount":94,"soonestReadout":110},[136],{"nctId":106,"briefTitle":107,"status":108,"phases":137,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":138,"interventions":139},[88],[115],[93,117,118,119,120,121],{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"intervention":118,"totalTrials":94,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":158,"NA":160},{"trials":147,"activeCount":98},[],{"trials":149,"activeCount":98},[],{"trials":151,"activeCount":98},[],{"trials":153,"activeCount":94,"soonestReadout":110},[154],{"nctId":106,"briefTitle":107,"status":108,"phases":155,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":156,"interventions":157},[88],[115],[93,117,118,119,120,121],{"trials":159,"activeCount":98},[],{"trials":161,"activeCount":98},[],{"intervention":119,"totalTrials":94,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":176,"NA":178},{"trials":165,"activeCount":98},[],{"trials":167,"activeCount":98},[],{"trials":169,"activeCount":98},[],{"trials":171,"activeCount":94,"soonestReadout":110},[172],{"nctId":106,"briefTitle":107,"status":108,"phases":173,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":174,"interventions":175},[88],[115],[93,117,118,119,120,121],{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":98},[],{"intervention":120,"totalTrials":94,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":194,"NA":196},{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":98},[],{"trials":189,"activeCount":94,"soonestReadout":110},[190],{"nctId":106,"briefTitle":107,"status":108,"phases":191,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":192,"interventions":193},[88],[115],[93,117,118,119,120,121],{"trials":195,"activeCount":98},[],{"trials":197,"activeCount":98},[],{"intervention":121,"totalTrials":94,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":212,"NA":214},{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":94,"soonestReadout":110},[208],{"nctId":106,"briefTitle":107,"status":108,"phases":209,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":210,"interventions":211},[88],[115],[93,117,118,119,120,121],{"trials":213,"activeCount":98},[],{"trials":215,"activeCount":98},[],{"intervention":217,"totalTrials":94,"cells":218},"Anakinra",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":239,"NA":241},{"trials":220,"activeCount":98},[],{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":94,"soonestReadout":232},[227],{"nctId":228,"briefTitle":229,"status":230,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT05267821","Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS","RECRUITING",[87,88],"2028-05-15","2028-08-31","2022-06-14",500,[237],"Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)",[217],{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"intervention":244,"totalTrials":245,"cells":246},"Temozolomide",3,{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":297,"PHASE4":299,"NA":301},{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":98},[],{"trials":252,"activeCount":245,"soonestReadout":68},[253,273,285],{"nctId":254,"briefTitle":255,"status":230,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":270},"NCT05843253","Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant",[87],"2029-08-31","2034-08-28","2024-08-22",120,[15,21,262,263,264,265,266,267,268,269],"Anaplastic Astrocytoma","Glioblastoma","Glioblastoma Multiforme","Diffuse Midline Glioma, H3 K27M-Mutant","Metastatic Brain Tumor","WHO Grade III Glioma","WHO Grade IV Glioma","Diffuse Hemispheric Glioma, H3 G34-Mutant",[271,272,244],"Ribociclib","Everolimus",{"nctId":66,"briefTitle":67,"status":230,"phases":274,"primaryCompletion":68,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":281},[86,87],"2027-12","2022-09-01",31,[279,280],"Relapsed Neuroblastoma","Refractory Neuroblastoma",[69,244,282,283,284],"Irinotecan","Dinutuximab","Sargramostim",{"nctId":286,"briefTitle":287,"status":230,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":260,"conditions":292,"interventions":294},"NCT05096481","PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma",[87],"2028-06-15","2030-06-15","2024-07-18",[15,21,293],"Recurrent Medulloblastoma",[295,244,296],"PEP-CMV","Tetanus Diphtheria Vaccine",{"trials":298,"activeCount":98},[],{"trials":300,"activeCount":98},[],{"trials":302,"activeCount":98},[],{"intervention":304,"totalTrials":94,"cells":305},"Universal donor derived CD33 CAR-NK",{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":94,"soonestReadout":316},[312],{"nctId":313,"briefTitle":314,"status":108,"phases":315,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":322},"NCT07026942","Phase I\u002FII Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML",[86,87],"2032-07-01","2038-07-01","2026-04-01",42,[321],"Relapsed\u002FRefractory AML",[304],{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"intervention":330,"totalTrials":94,"cells":331},"Tocilizumab",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":98},[],{"trials":337,"activeCount":94,"soonestReadout":275},[338],{"nctId":339,"briefTitle":340,"status":230,"phases":341,"primaryCompletion":275,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":348},"NCT05233397","ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma",[87],"2029-12","2022-12-16",30,[346,347],"Adamantinomatous Craniopharyngioma","Recurrent Adamantinomatous Craniopharyngioma",[330],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":98},[],{"trials":354,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":358,"activeCount":98},[],{"trials":360,"activeCount":98},[],{"trials":362,"activeCount":94,"soonestReadout":82},[363],{"nctId":80,"briefTitle":81,"status":230,"phases":364,"primaryCompletion":82,"completion":82,"start":365,"enrollment":9,"conditions":366,"interventions":368},[86,87],"2022-02-14",[367],"Acute Myeloid Leukemia",[83],{"trials":370,"activeCount":98},[],{"trials":372,"activeCount":98},[],{"trials":374,"activeCount":98},[],{"intervention":271,"totalTrials":94,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":378,"activeCount":98},[],{"trials":380,"activeCount":98},[],{"trials":382,"activeCount":94,"soonestReadout":257},[383],{"nctId":254,"briefTitle":255,"status":230,"phases":384,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":385,"interventions":386},[87],[15,21,262,263,264,265,266,267,268,269],[271,272,244],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"trials":392,"activeCount":98},[],{"intervention":272,"totalTrials":94,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":98},[],{"trials":400,"activeCount":94,"soonestReadout":257},[401],{"nctId":254,"briefTitle":255,"status":230,"phases":402,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":403,"interventions":404},[87],[15,21,262,263,264,265,266,267,268,269],[271,272,244],{"trials":406,"activeCount":98},[],{"trials":408,"activeCount":98},[],{"trials":410,"activeCount":98},[],{"intervention":412,"totalTrials":94,"cells":413},"Tovorafenib",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"trials":419,"activeCount":94,"soonestReadout":424},[420],{"nctId":421,"briefTitle":422,"status":108,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":433},"NCT07206849","Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)",[87],"2030-05","2037-05","2026-05",79,[429,430,21,15,431,432,266],"High Grade Glioma (HGG) of the Brain With BRAF Aberration","High Grade Glioma (III or IV)","WHO Grade 3 Glioma","WHO Grade 4 Glioma",[412],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":94,"soonestReadout":68},[448],{"nctId":66,"briefTitle":67,"status":230,"phases":449,"primaryCompletion":68,"completion":275,"start":276,"enrollment":277,"conditions":450,"interventions":451},[86,87],[279,280],[69,244,282,283,284],{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"intervention":282,"totalTrials":94,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":98},[],{"trials":465,"activeCount":94,"soonestReadout":68},[466],{"nctId":66,"briefTitle":67,"status":230,"phases":467,"primaryCompletion":68,"completion":275,"start":276,"enrollment":277,"conditions":468,"interventions":469},[86,87],[279,280],[69,244,282,283,284],{"trials":471,"activeCount":98},[],{"trials":473,"activeCount":98},[],{"trials":475,"activeCount":98},[],{"intervention":283,"totalTrials":94,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":479,"activeCount":98},[],{"trials":481,"activeCount":98},[],{"trials":483,"activeCount":94,"soonestReadout":68},[484],{"nctId":66,"briefTitle":67,"status":230,"phases":485,"primaryCompletion":68,"completion":275,"start":276,"enrollment":277,"conditions":486,"interventions":487},[86,87],[279,280],[69,244,282,283,284],{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[],{"intervention":284,"totalTrials":94,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":497,"activeCount":98},[],{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":94,"soonestReadout":68},[502],{"nctId":66,"briefTitle":67,"status":230,"phases":503,"primaryCompletion":68,"completion":275,"start":276,"enrollment":277,"conditions":504,"interventions":505},[86,87],[279,280],[69,244,282,283,284],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"intervention":513,"totalTrials":94,"cells":514},"LUTATHERA®",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":94,"soonestReadout":525},[521],{"nctId":522,"briefTitle":523,"status":230,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":540},"NCT05278208","Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors",[86,87],"2028-11","2033-11","2022-11-21",65,[15,530,531,115,532,533,534,293,535,536,537,538,539],"Meningioma","Embryonal Tumor","Anaplastic Ependymoma","Recurrent Diffuse Intrinsic Pontine Glioma","Recurrent Malignant Glioma","Recurrent Primary Central Nervous System Neoplasm","Refractory Diffuse Intrinsic Pontine Glioma","Refractory Malignant Glioma","Refractory Medulloblastoma","Refractory Primary Central Nervous System Neoplasm",[513],{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":98},[],{"intervention":548,"totalTrials":94,"cells":549},"ACT001",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":98},[],{"trials":555,"activeCount":94,"soonestReadout":560},[556],{"nctId":557,"briefTitle":558,"status":230,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":570},"NCT06838676","ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas",[87],"2028-07","2035-07","2025-07-10",60,[565,566,567,568,569],"Diffuse Intrinsic Pontine Gliomas (DIPG)","Progressive DIPG","Refractory DIPG","Recurrent DIPG","H3K27-altered High Grade Glioma",[548],{"trials":572,"activeCount":98},[],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[],{"intervention":578,"totalTrials":94,"cells":579},"scAAV1.tMCK.NTF3",{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":94,"soonestReadout":590},[586],{"nctId":587,"briefTitle":588,"status":108,"phases":589,"primaryCompletion":590,"completion":591,"start":592,"enrollment":245,"conditions":593,"interventions":595},"NCT03520751","Phase I\u002FIIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A",[86,87],"2029-04","2030-04","2027-04",[594],"Charcot-Marie-Tooth Neuropathy Type 1A",[578],{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":605,"activeCount":98},[],{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":94,"soonestReadout":73},[610],{"nctId":76,"briefTitle":77,"status":230,"phases":611,"primaryCompletion":73,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":618},[86,87],"2027-12-01","2022-11-14",50,[616,617],"Pediatric Sarcoma, Refractory","Pediatric Sarcoma, Relapsed",[78],{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":98},[],{"intervention":295,"totalTrials":94,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[],{"trials":632,"activeCount":94,"soonestReadout":289},[633],{"nctId":286,"briefTitle":287,"status":230,"phases":634,"primaryCompletion":289,"completion":290,"start":291,"enrollment":260,"conditions":635,"interventions":636},[87],[15,21,293],[295,244,296],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[],{"intervention":296,"totalTrials":94,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[],{"trials":650,"activeCount":94,"soonestReadout":289},[651],{"nctId":286,"briefTitle":287,"status":230,"phases":652,"primaryCompletion":289,"completion":290,"start":291,"enrollment":260,"conditions":653,"interventions":654},[87],[15,21,293],[295,244,296],{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":98},[],{"trials":660,"activeCount":98},[],{"intervention":59,"totalTrials":94,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":94,"soonestReadout":58},[669],{"nctId":56,"briefTitle":57,"status":230,"phases":670,"primaryCompletion":58,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":686},[87],"2027-08","2020-07-15",24,[675,676,677,678,679,680,681,682,683,684,685],"HLH - Hypoplastic Left Heart Syndrome","DORV","DILV - Double Inlet Left Ventricle","Mitral Atresia","Tricuspid Atresia","Unbalanced AV Canal","Single-ventricle","Heart Defects, Congenital","Cardiovascular Abnormalities","Cardiovascular Diseases","Heart Diseases",[59],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":94,"soonestReadout":53},[701],{"nctId":51,"briefTitle":52,"status":230,"phases":702,"primaryCompletion":53,"completion":342,"start":703,"enrollment":704,"conditions":705,"interventions":708},[87],"2022-07-20",86,[706,707],"Neuroblastoma","Sarcoma",[54],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":718,"activeCount":98},[],{"trials":720,"activeCount":98},[],{"trials":722,"activeCount":94,"soonestReadout":43},[723],{"nctId":41,"briefTitle":42,"status":724,"phases":725,"primaryCompletion":43,"completion":43,"start":726,"enrollment":528,"conditions":727,"interventions":729},"ACTIVE_NOT_RECRUITING",[87],"2014-03-01",[728],"MIBG Avid Tumors",[44],{"trials":731,"activeCount":98},[],{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"intervention":737,"totalTrials":94,"cells":738},"Binimetinib Oral Tablet [Mektovi]",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":94,"soonestReadout":749},[745],{"nctId":746,"briefTitle":747,"status":230,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT05286788","MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma",[87],"2027-04-10","2023-04-10",38,[753,347],"Adamantinous Craniopharyngioma",[737],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":94,"soonestReadout":63},[769],{"nctId":61,"briefTitle":62,"status":230,"phases":770,"primaryCompletion":63,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":776},[86,87],"2027-10-01","2021-10-01",12,[775],"Adenovirus Infection",[64],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"intervention":784,"totalTrials":94,"cells":785},"NK cells",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":94,"soonestReadout":794},[790],{"nctId":791,"briefTitle":792,"status":230,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT04254419","Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells",[86],"2030-12-31","2031-10","2025-03-04",18,[15],[784],{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"intervention":39,"totalTrials":94,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":94,"soonestReadout":38},[814],{"nctId":36,"briefTitle":37,"status":724,"phases":815,"primaryCompletion":38,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":820},[86],"2029-03-01","2018-08-01",64,[15,21],[39],{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":830},{"EARLY_PHASE1":831,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":832,"activeCount":94,"soonestReadout":73},[833],{"nctId":71,"briefTitle":72,"status":230,"phases":834,"primaryCompletion":73,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":839},[85],"2036-12-01","2021-04-08",15,[15,21],[74],{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[],{"intervention":851,"totalTrials":94,"cells":852},"CD19 specific Chimeric Antigen Receptor T Cell",{"EARLY_PHASE1":853,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":854,"activeCount":94,"soonestReadout":859},[855],{"nctId":856,"briefTitle":857,"status":108,"phases":858,"primaryCompletion":859,"completion":860,"start":861,"enrollment":773,"conditions":862,"interventions":869},"NCT05779930","Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed\u002FRefractory CD19 Positive ALL and NHL",[85],"2030-12","2035-12","2025-10",[863,864,865,866,867,868],"Acute Lymphoblastic Leukemia, in Relapse","Non-Hodgkin's Lymphoma, Relapsed","Non-Hodgkin's Lymphoma Refractory","Acute Lymphoblastic Leukemia With Failed Remission","B-cell Non Hodgkin Lymphoma","B Cell Leukemia",[851],{"trials":871,"activeCount":98},[],{"trials":873,"activeCount":98},[],{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"intervention":881,"totalTrials":94,"cells":882},"Lorlatinib",{"EARLY_PHASE1":883,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":884,"activeCount":94,"soonestReadout":889},[885],{"nctId":886,"briefTitle":887,"status":230,"phases":888,"primaryCompletion":889,"completion":890,"start":891,"enrollment":837,"conditions":892,"interventions":895},"NCT06333899","Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion",[85],"2029-07-01","2035-06-01","2025-08-03",[15,21,262,893,263,264,267,268,894],"Infant Type Hemispheric Glioma","Diffuse Midline Glioma, H3K27-altered",[881,896,897,898],"Lorlatinib with chemotherapy1","Lorlatinib with chemotherapy 2","Lorlatinib post Radiation",{"trials":900,"activeCount":98},[],{"trials":902,"activeCount":98},[],{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"intervention":896,"totalTrials":94,"cells":910},{"EARLY_PHASE1":911,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":912,"activeCount":94,"soonestReadout":889},[913],{"nctId":886,"briefTitle":887,"status":230,"phases":914,"primaryCompletion":889,"completion":890,"start":891,"enrollment":837,"conditions":915,"interventions":916},[85],[15,21,262,893,263,264,267,268,894],[881,896,897,898],{"trials":918,"activeCount":98},[],{"trials":920,"activeCount":98},[],{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":98},[],{"intervention":897,"totalTrials":94,"cells":928},{"EARLY_PHASE1":929,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":930,"activeCount":94,"soonestReadout":889},[931],{"nctId":886,"briefTitle":887,"status":230,"phases":932,"primaryCompletion":889,"completion":890,"start":891,"enrollment":837,"conditions":933,"interventions":934},[85],[15,21,262,893,263,264,267,268,894],[881,896,897,898],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":98},[],{"trials":942,"activeCount":98},[],{"trials":944,"activeCount":98},[],{"intervention":898,"totalTrials":94,"cells":946},{"EARLY_PHASE1":947,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":948,"activeCount":94,"soonestReadout":889},[949],{"nctId":886,"briefTitle":887,"status":230,"phases":950,"primaryCompletion":889,"completion":890,"start":891,"enrollment":837,"conditions":951,"interventions":952},[85],[15,21,262,893,263,264,267,268,894],[881,896,897,898],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[],{"intervention":964,"totalTrials":94,"cells":965},"Omeprazole",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":976},{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":94,"soonestReadout":525},[978],{"nctId":979,"briefTitle":980,"status":230,"phases":981,"primaryCompletion":525,"completion":525,"start":982,"enrollment":983,"conditions":984,"interventions":986},"NCT06114836","GERD Infant Feeding Therapeutics Trial (GIFT Trial)",[90],"2024-03-14",369,[985],"GERD in Infants",[964],{"intervention":988,"totalTrials":94,"cells":989},"PIONEER Protocol",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":991,"activeCount":98},[],{"trials":993,"activeCount":98},[],{"trials":995,"activeCount":98},[],{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":94,"soonestReadout":1006},[1002],{"nctId":1003,"briefTitle":1004,"status":108,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":112,"enrollment":1008,"conditions":1009,"interventions":1012},"NCT07035912","Novel PIONEER© Protocol: RCT",[90],"2031-06-30","2032-06-30",134,[1010,1011],"Deglutition Disorders in Infants","Chronic Tube Feeding in Hospitalized Infants",[988],{"intervention":49,"totalTrials":94,"cells":1014},{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":98},[],{"trials":1026,"activeCount":94,"soonestReadout":48},[1027],{"nctId":46,"briefTitle":47,"status":230,"phases":1028,"primaryCompletion":48,"completion":48,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1033},[90],"2023-02-21",240,[1032],"Ductus Arteriosus, Patent",[49],{"intervention":1035,"totalTrials":94,"cells":1036},"Genetic characterization",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1038,"activeCount":98},[],{"trials":1040,"activeCount":98},[],{"trials":1042,"activeCount":98},[],{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":94,"soonestReadout":859},[1049],{"nctId":1050,"briefTitle":1051,"status":724,"phases":1052,"primaryCompletion":859,"completion":859,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1058},"NCT02972580","Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD",[],"2016-06",250,[1056,1057],"Duchenne Muscular Dystrophy","Becker Muscular Dystrophy",[1035],{"intervention":1060,"totalTrials":245,"cells":1061},"Dexamethasone",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1088,"PHASE4":1101,"NA":1112},{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[1068],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":1072,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":1076,"interventions":1079},"NCT01691690","Analgesic Effect of IV Acetaminophen in Tonsillectomies","COMPLETED",[87],"2015-11","2016-07","2012-10",[1077,1078],"Adenotonsillitis","Tonsillitis",[1080,1081,1082,1083,1084,1085,1086,1087,1060],"Acetaminophen","Normal Saline Flush","Midazolam","Sevoflurane","Nitrous Oxide\u002FOxygen","Propofol","Morphine","Ondansetron",{"trials":1089,"activeCount":98},[1090],{"nctId":1091,"briefTitle":1092,"status":1071,"phases":1093,"primaryCompletion":1074,"completion":1094,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1099},"NCT01971645","Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy",[88],"2016-09","2014-07",77,[1098],"Knee Injury",[1060,1100],"Ropivacaine",{"trials":1102,"activeCount":98},[1103],{"nctId":1104,"briefTitle":1105,"status":1071,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1053,"enrollment":1108,"conditions":1109,"interventions":1111},"NCT02793011","Dexamethasone and Post-tonsillectomy Pain in Children",[89],"2019-06-27",137,[1110],"Pediatric Post-tonsillectomy Pain",[1060],{"trials":1113,"activeCount":98},[],{"intervention":1115,"totalTrials":1116,"cells":1117},"GM-CSF",2,{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1135,"NA":1147},{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[1126],{"nctId":1127,"briefTitle":1128,"status":1071,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":234,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT05266001","GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS",[88],"2025-09-10",141,[1133],"Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome",[1115],{"trials":1136,"activeCount":98},[1137],{"nctId":1138,"briefTitle":1139,"status":1071,"phases":1140,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1146},"NCT03769844","GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study",[89],"2023-12-05","2018-12-05",75,[1145],"Pediatric Sepsis-induced MODS",[1115],{"trials":1148,"activeCount":98},[],{"intervention":1150,"totalTrials":94,"cells":1151},"DDAVP Inhalant Product",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1160,"NA":1173},{"trials":1153,"activeCount":98},[],{"trials":1155,"activeCount":98},[],{"trials":1157,"activeCount":98},[],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[1162],{"nctId":1163,"briefTitle":1164,"status":1071,"phases":1165,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1170,"interventions":1172},"NCT03379974","Exercise Versus DDAVP in Patients With Mild Hemophilia A",[89],"2019-08-30","2019-12-05","2018-07-31",32,[1171],"Hemophilia A",[1150],{"trials":1174,"activeCount":98},[],{"intervention":1176,"totalTrials":94,"cells":1177},"Tranexamic Acid",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1197},{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[],{"trials":1183,"activeCount":98},[],{"trials":1185,"activeCount":98},[],{"trials":1187,"activeCount":98},[1188],{"nctId":1189,"briefTitle":1190,"status":1071,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1169,"conditions":1194,"interventions":1196},"NCT01846507","Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding",[89],"2016-11","2013-04",[1195],"Heavy Menstrual Bleeding",[1176],{"trials":1198,"activeCount":98},[],{"intervention":1100,"totalTrials":245,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1227,"PHASE4":1233,"NA":1235},{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[1207,1216],{"nctId":1208,"briefTitle":1209,"status":1210,"phases":1211,"primaryCompletion":1095,"completion":1095,"start":1075,"enrollment":245,"conditions":1212,"interventions":1214},"NCT01575028","Transversus Abdominis Plane (TAP) Versus Local Anesthetic for Lap Appendectomies","TERMINATED",[87],[1213],"Appendicitis",[1100,1215],"Bupivacaine",{"nctId":1217,"briefTitle":1218,"status":1219,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":98,"conditions":1223,"interventions":1225},"NCT01293149","Clonidine in Femoral Nerve Block Surgery in Children","WITHDRAWN",[87],"2013-03","2011-04",[1224],"Other Reconstructive Surgery",[1100,1226],"Clonidine",{"trials":1228,"activeCount":98},[1229],{"nctId":1091,"briefTitle":1092,"status":1071,"phases":1230,"primaryCompletion":1074,"completion":1094,"start":1095,"enrollment":1096,"conditions":1231,"interventions":1232},[88],[1098],[1060,1100],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"intervention":1238,"totalTrials":1116,"cells":1239},"Rituximab",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1262,"PHASE4":1275,"NA":1277},{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[1246],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},"NCT01279616","A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease",[87],"2015-01","2010-09",8,[1254],"Sickle Cell Disease",[1256,1238,1257,1258,1259,1260,1261],"Fludarabine monophosphate","Busulfan","ATG","Cyclophosphamide","Mycophenolate mofetil","Tacrolimus",{"trials":1263,"activeCount":98},[1264],{"nctId":1265,"briefTitle":1266,"status":1210,"phases":1267,"primaryCompletion":1268,"completion":1269,"start":1250,"enrollment":245,"conditions":1270,"interventions":1273},"NCT02390362","Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome",[88],"2016-12-07","2017-01-18",[1271,1272],"Frequent Relapsing Nephrotic Syndrome","Steroid Dependent Nephrotic Syndrome",[1238,1274],"MMF",{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[],{"intervention":1082,"totalTrials":1116,"cells":1280},{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1291,"PHASE4":1305,"NA":1307},{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[1287],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":1288,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":1289,"interventions":1290},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":1292,"activeCount":98},[1293],{"nctId":1294,"briefTitle":1295,"status":1071,"phases":1296,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1302},"NCT01188551","Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement",[87,88],"2012-04","2011-01",100,[1301],"Chronic Otitis Media",[1303,1304,1082],"Dexmedetomidine","Fentanyl",{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[],{"intervention":1215,"totalTrials":1116,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1321,"PHASE4":1332,"NA":1334},{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[1317],{"nctId":1208,"briefTitle":1209,"status":1210,"phases":1318,"primaryCompletion":1095,"completion":1095,"start":1075,"enrollment":245,"conditions":1319,"interventions":1320},[87],[1213],[1100,1215],{"trials":1322,"activeCount":98},[1323],{"nctId":1324,"briefTitle":1325,"status":1210,"phases":1326,"primaryCompletion":1094,"completion":1094,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1331},"NCT01394523","Caudal Versus Rectus Sheath Study",[87,88],"2011-08",39,[1330],"Umbilical Hernia",[1215],{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"intervention":1304,"totalTrials":1116,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1357,"PHASE4":1363,"NA":1365},{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":98},[1344],{"nctId":1345,"briefTitle":1346,"status":1071,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1355},"NCT00848393","Measures to Lower the Stress Response in Pediatric Cardiac Surgery",[87],"2013-12","2008-11",52,[1352,1353,1354],"Tetralogy of Fallot (TOF)","Ventricular Septal Defects (VSD)","Atrioventricular Septal Defects (AVSD)",[1304,1304,1356],"Fentanyl (Low Dose) + Dexmedetomidine",{"trials":1358,"activeCount":98},[1359],{"nctId":1294,"briefTitle":1295,"status":1071,"phases":1360,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1361,"interventions":1362},[87,88],[1301],[1303,1304,1082],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"intervention":1368,"totalTrials":94,"cells":1369},"Clevidipine",{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1374,"PHASE3":1376,"PHASE4":1386,"NA":1388},{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":98},[1378],{"nctId":1379,"briefTitle":1380,"status":1071,"phases":1381,"primaryCompletion":1348,"completion":1348,"start":1382,"enrollment":614,"conditions":1383,"interventions":1385},"NCT01645111","An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion",[87,88],"2012-06",[1384],"Neuromuscular Scoliosis",[1368],{"trials":1387,"activeCount":98},[],{"trials":1389,"activeCount":98},[],{"intervention":1391,"totalTrials":94,"cells":1392},"Depot medroxyprogesterone acetate",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1413,"NA":1415},{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[1401],{"nctId":1402,"briefTitle":1403,"status":1071,"phases":1404,"primaryCompletion":1405,"completion":1074,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1412},"NCT01461824","Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects",[88],"2015-04","2011-09",34,[1409,1410,1411],"Weight Gain","Disorder of Bone Density and Structure, Unspecified","Uterine Bleeding",[1391],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"intervention":1418,"totalTrials":94,"cells":1419},"Isoflurane",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1439,"NA":1441},{"trials":1421,"activeCount":98},[],{"trials":1423,"activeCount":98},[],{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[1428],{"nctId":1429,"briefTitle":1430,"status":1210,"phases":1431,"primaryCompletion":1432,"completion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1438},"NCT02512809","Isoflurane-induced Neuroinflammation in Children With Hydrocephalus",[88],"2017-10-31","2015-07",25,[1436,1437],"Toxicity","Hydrocephalus",[1418,1303],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"intervention":1444,"totalTrials":94,"cells":1445},"insulin detemir [rDNA origin]",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1464,"NA":1466},{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[1454],{"nctId":1455,"briefTitle":1456,"status":1210,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1463},"NCT00639626","Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)",[87,88],"2010-05","2008-08",6,[1462],"Cystic Fibrosis Related Diabetes",[1444],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[],{"intervention":1274,"totalTrials":94,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":98},[],{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[1478],{"nctId":1265,"briefTitle":1266,"status":1210,"phases":1479,"primaryCompletion":1268,"completion":1269,"start":1250,"enrollment":245,"conditions":1480,"interventions":1481},[88],[1271,1272],[1238,1274],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[],{"intervention":1487,"totalTrials":94,"cells":1488},"somatropin",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1507,"NA":1509},{"trials":1490,"activeCount":98},[],{"trials":1492,"activeCount":98},[],{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[1497],{"nctId":1498,"briefTitle":1499,"status":1071,"phases":1500,"primaryCompletion":1501,"completion":1501,"start":1502,"enrollment":245,"conditions":1503,"interventions":1506},"NCT00943995","Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis",[88],"2012-08","2010-07",[1504,1505],"Kidney Failure, Chronic","Renal Dialysis",[1487],{"trials":1508,"activeCount":98},[],{"trials":1510,"activeCount":98},[],{"intervention":1512,"totalTrials":94,"cells":1513},"rhIGF",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1530,"NA":1532},{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[],{"trials":1521,"activeCount":98},[1522],{"nctId":1523,"briefTitle":1524,"status":1210,"phases":1525,"primaryCompletion":1458,"completion":1458,"start":1526,"enrollment":245,"conditions":1527,"interventions":1529},"NCT00764699","Effect of Increlex® on Children With Crohn Disease",[87,88],"2008-10",[1528],"Crohn Disease",[1512],{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[],{"intervention":1535,"totalTrials":94,"cells":1536},"somatropin [rDNA origin] for",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1554,"NA":1556},{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[1545],{"nctId":1546,"briefTitle":1547,"status":1210,"phases":1548,"primaryCompletion":1458,"completion":1458,"start":1549,"enrollment":1550,"conditions":1551,"interventions":1553},"NCT00511329","Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease",[87,88],"2007-08",10,[1552,1528],"Arthritis, Juvenile Rheumatoid",[1535],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"intervention":1559,"totalTrials":94,"cells":1560},"Ropivacaine Hcl 0.5% Inj Vil 20Ml",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1578,"NA":1580},{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[1569],{"nctId":1570,"briefTitle":1571,"status":1071,"phases":1572,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":837,"conditions":1575,"interventions":1577},"NCT03746951","Comparative Evaluation of Lumbar Plexus and Suprainguinal Fascia Iliaca Compartment Blocks",[87,88],"2020-01-31","2019-04-24",[1576],"Orthopedic Disorder",[1559],{"trials":1579,"activeCount":98},[],{"trials":1581,"activeCount":98},[],{"intervention":1583,"totalTrials":94,"cells":1584},"Baclofen",{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1591,"PHASE4":1603,"NA":1605},{"trials":1586,"activeCount":98},[],{"trials":1588,"activeCount":98},[],{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[1593],{"nctId":1594,"briefTitle":1595,"status":1071,"phases":1596,"primaryCompletion":1597,"completion":1598,"start":1599,"enrollment":614,"conditions":1600,"interventions":1602},"NCT05975684","Baclofen for Children With Rumination Syndrome",[88],"2024-07-31","2025-01-27","2023-01-31",[1601],"Rumination Syndrome",[1583],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"intervention":1608,"totalTrials":94,"cells":1609},"Normal Saline",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1630,"NA":1632},{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[1618],{"nctId":1619,"briefTitle":1620,"status":1071,"phases":1621,"primaryCompletion":1622,"completion":1622,"start":1623,"enrollment":1624,"conditions":1625,"interventions":1627},"NCT03054922","Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables",[88],"2018-09-30","2017-02-23",59,[1626],"Anesthesia",[1608,1628,1629],"Lactated Ringer","Normosol-R Inj",{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"intervention":1628,"totalTrials":94,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1642,"PHASE4":1648,"NA":1650},{"trials":1637,"activeCount":98},[],{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[1644],{"nctId":1619,"briefTitle":1620,"status":1071,"phases":1645,"primaryCompletion":1622,"completion":1622,"start":1623,"enrollment":1624,"conditions":1646,"interventions":1647},[88],[1626],[1608,1628,1629],{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":98},[],{"intervention":1629,"totalTrials":94,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1660,"PHASE4":1666,"NA":1668},{"trials":1655,"activeCount":98},[],{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[1662],{"nctId":1619,"briefTitle":1620,"status":1071,"phases":1663,"primaryCompletion":1622,"completion":1622,"start":1623,"enrollment":1624,"conditions":1664,"interventions":1665},[88],[1626],[1608,1628,1629],{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[],{"intervention":1671,"totalTrials":94,"cells":1672},"Risperidone",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1692,"NA":1694},{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[1681],{"nctId":1682,"briefTitle":1683,"status":1071,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1690},"NCT02456454","Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder",[88],"2010-06","2006-01",46,[1689],"Bipolar Disorder",[1671,1691],"Valproic Acid",{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"intervention":1691,"totalTrials":94,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1710,"NA":1712},{"trials":1699,"activeCount":98},[],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[1706],{"nctId":1682,"briefTitle":1683,"status":1071,"phases":1707,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":1687,"conditions":1708,"interventions":1709},[88],[1689],[1671,1691],{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"intervention":1257,"totalTrials":1116,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1717,"activeCount":98},[],{"trials":1719,"activeCount":98},[],{"trials":1721,"activeCount":98},[1722,1726],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1723,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1724,"interventions":1725},[87],[1254],[1256,1238,1257,1258,1259,1260,1261],{"nctId":1727,"briefTitle":1728,"status":1219,"phases":1729,"primaryCompletion":1382,"completion":1382,"start":1730,"enrollment":98,"conditions":1731,"interventions":1732},"NCT00874315","Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.",[87],"2008-09",[706],[1733,1734,1735,1736,1737],"busulfan","cyclosporine","fludarabine phosphate","mycophenolate mofetil","tacrolimus",{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"intervention":1260,"totalTrials":1116,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1747,"activeCount":98},[],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[1752,1756],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1753,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1754,"interventions":1755},[87],[1254],[1256,1238,1257,1258,1259,1260,1261],{"nctId":1727,"briefTitle":1728,"status":1219,"phases":1757,"primaryCompletion":1382,"completion":1382,"start":1730,"enrollment":98,"conditions":1758,"interventions":1759},[87],[706],[1733,1734,1735,1736,1737],{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[],{"trials":1765,"activeCount":98},[],{"intervention":1261,"totalTrials":1116,"cells":1767},{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1782,"PHASE4":1784,"NA":1786},{"trials":1769,"activeCount":98},[],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[1774,1778],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1775,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1776,"interventions":1777},[87],[1254],[1256,1238,1257,1258,1259,1260,1261],{"nctId":1727,"briefTitle":1728,"status":1219,"phases":1779,"primaryCompletion":1382,"completion":1382,"start":1730,"enrollment":98,"conditions":1780,"interventions":1781},[87],[706],[1733,1734,1735,1736,1737],{"trials":1783,"activeCount":98},[],{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"intervention":1789,"totalTrials":94,"cells":1790},"Intranasal Dexmedetomidine",{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[1797],{"nctId":1798,"briefTitle":1799,"status":1219,"phases":1800,"primaryCompletion":861,"completion":861,"start":1801,"enrollment":98,"conditions":1802,"interventions":1805},"NCT05057689","Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room",[87],"2025-09",[1803,1804,33],"Acute Stress Disorder","Anxiety",[1789,1806,1807],"Intranasal Fentanyl","Intranasal Midazolam",{"trials":1809,"activeCount":98},[],{"trials":1811,"activeCount":98},[],{"trials":1813,"activeCount":98},[],{"intervention":1806,"totalTrials":94,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":98},[],{"trials":1819,"activeCount":98},[],{"trials":1821,"activeCount":98},[1822],{"nctId":1798,"briefTitle":1799,"status":1219,"phases":1823,"primaryCompletion":861,"completion":861,"start":1801,"enrollment":98,"conditions":1824,"interventions":1825},[87],[1803,1804,33],[1789,1806,1807],{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":98},[],{"trials":1831,"activeCount":98},[],{"intervention":1807,"totalTrials":94,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[1840],{"nctId":1798,"briefTitle":1799,"status":1219,"phases":1841,"primaryCompletion":861,"completion":861,"start":1801,"enrollment":98,"conditions":1842,"interventions":1843},[87],[1803,1804,33],[1789,1806,1807],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"intervention":1851,"totalTrials":94,"cells":1852},"Infliximab and Basiliximab",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1854,"activeCount":98},[],{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[1859],{"nctId":1860,"briefTitle":1861,"status":1210,"phases":1862,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":1867,"interventions":1871},"NCT01485055","Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease",[87],"2015-12","2016-09-26","2011-12",11,[1868,1869,1870],"Graft Versus Host Disease","Steroid Refractory GVHD","Acute GVH Disease",[1851],{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[],{"trials":1877,"activeCount":98},[],{"intervention":1879,"totalTrials":94,"cells":1880},"Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[],{"trials":1886,"activeCount":98},[1887],{"nctId":1888,"briefTitle":1889,"status":1071,"phases":1890,"primaryCompletion":1891,"completion":1892,"start":1893,"enrollment":1550,"conditions":1894,"interventions":1896},"NCT01270724","Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)",[87],"2019-10-23","2019-12-09","2010-08",[1895],"CNS Germ Cell Tumor",[1879],{"trials":1898,"activeCount":98},[],{"trials":1900,"activeCount":98},[],{"trials":1902,"activeCount":98},[],{"intervention":1256,"totalTrials":94,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[1911],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1912,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1913,"interventions":1914},[87],[1254],[1256,1238,1257,1258,1259,1260,1261],{"trials":1916,"activeCount":98},[],{"trials":1918,"activeCount":98},[],{"trials":1920,"activeCount":98},[],{"intervention":1258,"totalTrials":94,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[],{"trials":1928,"activeCount":98},[1929],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1930,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1931,"interventions":1932},[87],[1254],[1256,1238,1257,1258,1259,1260,1261],{"trials":1934,"activeCount":98},[],{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[],{"intervention":1259,"totalTrials":94,"cells":1940},{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[],{"trials":1946,"activeCount":98},[1947],{"nctId":1247,"briefTitle":1248,"status":1210,"phases":1948,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1949,"interventions":1950},[87],[1254],[1256,1238,1257,1258,1259,1260,1261],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"intervention":1080,"totalTrials":94,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1969,"PHASE4":1971,"NA":1973},{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[1965],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":1966,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":1967,"interventions":1968},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":1970,"activeCount":98},[],{"trials":1972,"activeCount":98},[],{"trials":1974,"activeCount":98},[],{"intervention":1081,"totalTrials":94,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1987,"PHASE4":1989,"NA":1991},{"trials":1978,"activeCount":98},[],{"trials":1980,"activeCount":98},[],{"trials":1982,"activeCount":98},[1983],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":1984,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":1985,"interventions":1986},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"intervention":1084,"totalTrials":94,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":98},[2001],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":2002,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":2003,"interventions":2004},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[],{"trials":2010,"activeCount":98},[],{"intervention":1086,"totalTrials":94,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[2019],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":2020,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":2021,"interventions":2022},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[],{"trials":2028,"activeCount":98},[],{"intervention":1087,"totalTrials":94,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2032,"activeCount":98},[],{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[2037],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":2038,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":2039,"interventions":2040},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"trials":2046,"activeCount":98},[],{"intervention":2048,"totalTrials":94,"cells":2049},"mobilization of stem cells to prepare for Leukapheresis",{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2051,"activeCount":98},[],{"trials":2053,"activeCount":98},[],{"trials":2055,"activeCount":98},[2056],{"nctId":2057,"briefTitle":2058,"status":1219,"phases":2059,"primaryCompletion":1193,"completion":1193,"start":1193,"enrollment":98,"conditions":2060,"interventions":2062},"NCT02676622","Autologous Stem Cell Transplant for Refractory Crohn's Disease",[87],[2061],"Crohn's Disease",[2048,2063,2064],"Preparative regimen 4-6 weeks after Leukapheresis","Low-dose IL-2 administration",{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[],{"intervention":2063,"totalTrials":94,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2074,"activeCount":98},[],{"trials":2076,"activeCount":98},[],{"trials":2078,"activeCount":98},[2079],{"nctId":2057,"briefTitle":2058,"status":1219,"phases":2080,"primaryCompletion":1193,"completion":1193,"start":1193,"enrollment":98,"conditions":2081,"interventions":2082},[87],[2061],[2048,2063,2064],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"intervention":2064,"totalTrials":94,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[2097],{"nctId":2057,"briefTitle":2058,"status":1219,"phases":2098,"primaryCompletion":1193,"completion":1193,"start":1193,"enrollment":98,"conditions":2099,"interventions":2100},[87],[2061],[2048,2063,2064],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"intervention":2108,"totalTrials":94,"cells":2109},"Methadone hydrochloride",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[2116],{"nctId":2117,"briefTitle":2118,"status":1071,"phases":2119,"primaryCompletion":2120,"completion":1094,"start":2121,"enrollment":2122,"conditions":2123,"interventions":2125},"NCT01795495","Methadone vs Magnesium in Spinal Fusion",[87],"2016-08","2013-09",63,[2124],"Idiopathic Scoliosis",[2108,2126,2127],"Magnesium Sulfate","Remifentanil",{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"intervention":2126,"totalTrials":94,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":98},[],{"trials":2141,"activeCount":98},[2142],{"nctId":2117,"briefTitle":2118,"status":1071,"phases":2143,"primaryCompletion":2120,"completion":1094,"start":2121,"enrollment":2122,"conditions":2144,"interventions":2145},[87],[2124],[2108,2126,2127],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"intervention":2127,"totalTrials":94,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[],{"trials":2159,"activeCount":98},[2160],{"nctId":2117,"briefTitle":2118,"status":1071,"phases":2161,"primaryCompletion":2120,"completion":1094,"start":2121,"enrollment":2122,"conditions":2162,"interventions":2163},[87],[2124],[2108,2126,2127],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"trials":2169,"activeCount":98},[],{"intervention":1734,"totalTrials":94,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[2178],{"nctId":1727,"briefTitle":1728,"status":1219,"phases":2179,"primaryCompletion":1382,"completion":1382,"start":1730,"enrollment":98,"conditions":2180,"interventions":2181},[87],[706],[1733,1734,1735,1736,1737],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[],{"intervention":1735,"totalTrials":94,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"trials":2195,"activeCount":98},[2196],{"nctId":1727,"briefTitle":1728,"status":1219,"phases":2197,"primaryCompletion":1382,"completion":1382,"start":1730,"enrollment":98,"conditions":2198,"interventions":2199},[87],[706],[1733,1734,1735,1736,1737],{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"intervention":2207,"totalTrials":94,"cells":2208},"Ropivicaine",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2226,"PHASE4":2228,"NA":2230},{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[2215],{"nctId":2216,"briefTitle":2217,"status":1210,"phases":2218,"primaryCompletion":2219,"completion":2219,"start":2220,"enrollment":2221,"conditions":2222,"interventions":2224},"NCT01759407","Femoral Nerve Block for Femur Fracture Repair in Pediatrics",[87],"2016-10","2013-05",19,[2223],"Traumatic Femur Fracture",[2207,2225],"Epinephrine",{"trials":2227,"activeCount":98},[],{"trials":2229,"activeCount":98},[],{"trials":2231,"activeCount":98},[],{"intervention":2225,"totalTrials":94,"cells":2233},{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2244,"PHASE4":2246,"NA":2248},{"trials":2235,"activeCount":98},[],{"trials":2237,"activeCount":98},[],{"trials":2239,"activeCount":98},[2240],{"nctId":2216,"briefTitle":2217,"status":1210,"phases":2241,"primaryCompletion":2219,"completion":2219,"start":2220,"enrollment":2221,"conditions":2242,"interventions":2243},[87],[2223],[2207,2225],{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[],{"intervention":2251,"totalTrials":94,"cells":2252},"Hydrocortisone",{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2257,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[2259],{"nctId":2260,"briefTitle":2261,"status":1071,"phases":2262,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":818,"conditions":2266,"interventions":2270},"NCT00167544","Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants",[87],"2009-01","2012-11","2005-11",[2267,2268,2269],"Bronchopulmonary Dysplasia","Encephalomalacia","Premature Birth",[2251],{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"intervention":2278,"totalTrials":94,"cells":2279},"Recombinant Human DNase",{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[2286],{"nctId":2287,"briefTitle":2288,"status":1071,"phases":2289,"primaryCompletion":1526,"completion":1074,"start":2290,"enrollment":673,"conditions":2291,"interventions":2293},"NCT00179998","Effectiveness of Pulmozyme in Infants With Cystic Fibrosis",[87],"2005-01",[2292],"Cystic Fibrosis",[2278,2294],"Placebos",{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[],{"trials":2300,"activeCount":98},[],{"intervention":2294,"totalTrials":94,"cells":2302},{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":98},[],{"trials":2308,"activeCount":98},[2309],{"nctId":2287,"briefTitle":2288,"status":1071,"phases":2310,"primaryCompletion":1526,"completion":1074,"start":2290,"enrollment":673,"conditions":2311,"interventions":2312},[87],[2292],[2278,2294],{"trials":2314,"activeCount":98},[],{"trials":2316,"activeCount":98},[],{"trials":2318,"activeCount":98},[],{"intervention":2320,"totalTrials":94,"cells":2321},"IV acetaminophen",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2336,"PHASE4":2338,"NA":2340},{"trials":2323,"activeCount":98},[],{"trials":2325,"activeCount":98},[],{"trials":2327,"activeCount":98},[2328],{"nctId":2329,"briefTitle":2330,"status":1219,"phases":2331,"primaryCompletion":2332,"completion":2332,"start":1863,"enrollment":98,"conditions":2333,"interventions":2335},"NCT01760330","IV Acetaminophen in Children Undergoing Palatoplasty",[87],"2016-12",[2334],"Cleft Palate",[2320],{"trials":2337,"activeCount":98},[],{"trials":2339,"activeCount":98},[],{"trials":2341,"activeCount":98},[],{"intervention":2343,"totalTrials":94,"cells":2344},"Ketorolac",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[2351],{"nctId":2352,"briefTitle":2353,"status":1219,"phases":2354,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":98,"conditions":2357,"interventions":2359},"NCT01667120","The Use of Ketorolac in Surgical Neonates",[87],"2018-12-31","2012-07",[2358],"Postoperative Pain Control in Surgical Neonates",[2343],{"trials":2361,"activeCount":98},[],{"trials":2363,"activeCount":98},[],{"trials":2365,"activeCount":98},[],{"intervention":1356,"totalTrials":94,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":98},[],{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[2374],{"nctId":1345,"briefTitle":1346,"status":1071,"phases":2375,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":2376,"interventions":2377},[87],[1352,1353,1354],[1304,1304,1356],{"trials":2379,"activeCount":98},[],{"trials":2381,"activeCount":98},[],{"trials":2383,"activeCount":98},[],{"intervention":2385,"totalTrials":94,"cells":2386},"rAAV2.5-CMV-minidystrophin",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2399,"PHASE3":2401,"PHASE4":2403,"NA":2405},{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[2391],{"nctId":2392,"briefTitle":2393,"status":1071,"phases":2394,"primaryCompletion":2395,"completion":1502,"start":2396,"enrollment":1460,"conditions":2397,"interventions":2398},"NCT00428935","Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy",[86],"2009-03","2006-03",[1056],[2385],{"trials":2400,"activeCount":98},[],{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[],{"intervention":2408,"totalTrials":94,"cells":2409},"Metformin",{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2424,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[2414],{"nctId":2415,"briefTitle":2416,"status":1071,"phases":2417,"primaryCompletion":2418,"completion":2220,"start":2419,"enrollment":113,"conditions":2420,"interventions":2423},"NCT01231074","Reducing Antipsychotic-Induced Weight Gain in Children With Metformin",[86],"2012-02","2010-02",[2421,1409,2422],"Obesity","Psychotropic Induced Weight Gain",[2408],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[],{"intervention":2433,"totalTrials":94,"cells":2434},"rAAV1.tMCK.human-alpha-sarcoglycan- First cohort",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[2439],{"nctId":2440,"briefTitle":2441,"status":1071,"phases":2442,"primaryCompletion":2443,"completion":1327,"start":2444,"enrollment":1460,"conditions":2445,"interventions":2447},"NCT00494195","Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)",[86],"2011-06","2008-03",[2446],"Muscular Dystrophies",[2433,2448],"Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort",{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"intervention":2448,"totalTrials":94,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2460,"activeCount":98},[],{"trials":2462,"activeCount":98},[2463],{"nctId":2440,"briefTitle":2441,"status":1071,"phases":2464,"primaryCompletion":2443,"completion":1327,"start":2444,"enrollment":1460,"conditions":2465,"interventions":2466},[86],[2446],[2433,2448],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[],{"intervention":2476,"totalTrials":94,"cells":2477},"Gentamicin infusions twice a week for six months",{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[2482],{"nctId":2483,"briefTitle":2484,"status":1071,"phases":2485,"primaryCompletion":2486,"completion":2486,"start":2487,"enrollment":773,"conditions":2488,"interventions":2489},"NCT00451074","Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons",[86],"2009-07","2007-03",[1056],[2476],{"trials":2491,"activeCount":98},[],{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"intervention":2499,"totalTrials":94,"cells":2500},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[2505],{"nctId":2506,"briefTitle":2507,"status":1071,"phases":2508,"primaryCompletion":1221,"completion":2509,"start":2419,"enrollment":26,"conditions":2510,"interventions":2513},"NCT01061099","Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta",[86],"2014-02",[2511,2512],"Osteogenesis Imperfecta Type II","Osteogenesis Imperfecta Type III",[2499],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":98},[],{"trials":2519,"activeCount":98},[],{"trials":2521,"activeCount":98},[],{"intervention":2523,"totalTrials":94,"cells":2524},"rAAV1.CMV.huFollistatin344",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[2529],{"nctId":2530,"briefTitle":2531,"status":1071,"phases":2532,"primaryCompletion":2533,"completion":2533,"start":2534,"enrollment":837,"conditions":2535,"interventions":2537},"NCT01519349","Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis",[86],"2017-10","2012-01",[1057,2536],"Sporadic Inclusion Body Myositis",[2523],{"trials":2539,"activeCount":98},[],{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[],{"trials":2545,"activeCount":98},[],{"intervention":2547,"totalTrials":94,"cells":2548},"Low Dose Cosyntropin (ACTH) stimulation test",{"EARLY_PHASE1":2549,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2550,"activeCount":98},[2551],{"nctId":2552,"briefTitle":2553,"status":1071,"phases":2554,"primaryCompletion":2555,"completion":2556,"start":2557,"enrollment":1550,"conditions":2558,"interventions":2562},"NCT03709381","Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study",[85],"2018-10-31","2019-01-31","2017-10-01",[2559,2560,2561],"Adrenal Insufficiency","Osteopenia, Osteoporosis","Steroid Suppression of ACTH Secretion",[2547,2563],"High Dose Cosyntropin (ACTH) stimulation test",{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"trials":2573,"activeCount":98},[],{"intervention":2563,"totalTrials":94,"cells":2575},{"EARLY_PHASE1":2576,"PHASE1":2582,"PHASE2":2584,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2577,"activeCount":98},[2578],{"nctId":2552,"briefTitle":2553,"status":1071,"phases":2579,"primaryCompletion":2555,"completion":2556,"start":2557,"enrollment":1550,"conditions":2580,"interventions":2581},[85],[2559,2560,2561],[2547,2563],{"trials":2583,"activeCount":98},[],{"trials":2585,"activeCount":98},[],{"trials":2587,"activeCount":98},[],{"trials":2589,"activeCount":98},[],{"trials":2591,"activeCount":98},[],{"intervention":1303,"totalTrials":31,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2610,"NA":2612},{"trials":2595,"activeCount":98},[],{"trials":2597,"activeCount":98},[],{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[2602,2606],{"nctId":1429,"briefTitle":1430,"status":1210,"phases":2603,"primaryCompletion":1432,"completion":1432,"start":1433,"enrollment":1434,"conditions":2604,"interventions":2605},[88],[1436,1437],[1418,1303],{"nctId":1294,"briefTitle":1295,"status":1071,"phases":2607,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":2608,"interventions":2609},[87,88],[1301],[1303,1304,1082],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[2614,2623],{"nctId":2615,"briefTitle":2616,"status":1219,"phases":2617,"primaryCompletion":2618,"completion":2618,"start":2619,"enrollment":98,"conditions":2620,"interventions":2622},"NCT02709200","Effect of Dexmedetomidine on Pacemaker Function Following Cardiac Surgery",[],"2019-03-11","2016-02",[2621],"Congenital Heart Disease",[1303],{"nctId":2624,"briefTitle":2625,"status":1071,"phases":2626,"primaryCompletion":1193,"completion":2627,"start":1327,"enrollment":2628,"conditions":2629,"interventions":2630},"NCT01645098","Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy",[90],"2013-06",53,[1056],[2631,1303],"Ketamine",{"intervention":2631,"totalTrials":1116,"cells":2633},{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2640,"PHASE4":2651,"NA":2653},{"trials":2635,"activeCount":98},[],{"trials":2637,"activeCount":98},[],{"trials":2639,"activeCount":98},[],{"trials":2641,"activeCount":98},[2642],{"nctId":2643,"briefTitle":2644,"status":2645,"phases":2646,"primaryCompletion":2647,"completion":2647,"start":2627,"enrollment":1550,"conditions":2648,"interventions":2650},"NCT02048423","An Open Prospective Trial of IV Ketamine in Suicidal Adolescents","UNKNOWN",[87,88],"2015-06",[2649],"Major Depressive Disorder",[2631],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[2655],{"nctId":2624,"briefTitle":2625,"status":1071,"phases":2656,"primaryCompletion":1193,"completion":2627,"start":1327,"enrollment":2628,"conditions":2657,"interventions":2658},[90],[1056],[2631,1303],{"intervention":2660,"totalTrials":1116,"cells":2661},"propofol",{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2672,"PHASE4":2674,"NA":2676},{"trials":2663,"activeCount":98},[],{"trials":2665,"activeCount":98},[],{"trials":2667,"activeCount":98},[2668],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":2669,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":2670,"interventions":2671},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[],{"trials":2677,"activeCount":98},[2678],{"nctId":2679,"briefTitle":2680,"status":1071,"phases":2681,"primaryCompletion":1193,"completion":2627,"start":2534,"enrollment":344,"conditions":2682,"interventions":2683},"NCT01549873","Anesthesia During Neurophysiologic Monitoring in Scoliosis Patients",[90],[2124],[2660,2684],"Desflurane",{"intervention":1226,"totalTrials":1116,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[2693],{"nctId":1217,"briefTitle":1218,"status":1219,"phases":2694,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":98,"conditions":2695,"interventions":2696},[87],[1224],[1100,1226],{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[2703],{"nctId":2704,"briefTitle":2705,"status":1071,"phases":2706,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":2709,"conditions":2710,"interventions":2711},"NCT06287151","Regional Anesthesia EMG Study",[90],"2025-02-28","2023-08-09",80,[23],[1226,1083],{"intervention":1083,"totalTrials":1116,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":98},[],{"trials":2717,"activeCount":98},[],{"trials":2719,"activeCount":98},[2720],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":2721,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":1054,"conditions":2722,"interventions":2723},[87],[1077,1078],[1080,1081,1082,1083,1084,1085,1086,1087,1060],{"trials":2725,"activeCount":98},[],{"trials":2727,"activeCount":98},[],{"trials":2729,"activeCount":98},[2730],{"nctId":2704,"briefTitle":2705,"status":1071,"phases":2731,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":2709,"conditions":2732,"interventions":2733},[90],[23],[1226,1083],{"intervention":2735,"totalTrials":94,"cells":2736},"Nissle 1917",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2738,"activeCount":98},[],{"trials":2740,"activeCount":98},[],{"trials":2742,"activeCount":98},[],{"trials":2744,"activeCount":98},[],{"trials":2746,"activeCount":98},[],{"trials":2748,"activeCount":98},[2749],{"nctId":2750,"briefTitle":2751,"status":1071,"phases":2752,"primaryCompletion":2753,"completion":2753,"start":2356,"enrollment":614,"conditions":2754,"interventions":2757},"NCT01696227","Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children",[],"2014-06",[2755,2756],"Recurrent UTIs","Catheter-Related Infections",[2735],{"intervention":2759,"totalTrials":94,"cells":2760},"N-Acetyl Cysteine",{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2762,"activeCount":98},[],{"trials":2764,"activeCount":98},[],{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":98},[],{"trials":2772,"activeCount":98},[2773],{"nctId":2774,"briefTitle":2775,"status":1219,"phases":2776,"primaryCompletion":1250,"completion":1250,"start":1193,"enrollment":98,"conditions":2777,"interventions":2781},"NCT02054949","Treatment Resistant Epilepsy and N-Acetyl Cysteine",[90],[2778,2779,2780],"Autistic Disorder","Seizures","Irritability",[2759],{"intervention":2783,"totalTrials":94,"cells":2784},"Amphetamine and\u002For methylphenidate",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[],{"trials":2796,"activeCount":98},[2797],{"nctId":2798,"briefTitle":2799,"status":1071,"phases":2800,"primaryCompletion":1863,"completion":1863,"start":2264,"enrollment":614,"conditions":2801,"interventions":2803},"NCT01740206","Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)",[90],[2802],"Attention Deficit Hyperactivity Disorder",[2783],{"intervention":2684,"totalTrials":94,"cells":2805},{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2812,"PHASE4":2814,"NA":2816},{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[],{"trials":2815,"activeCount":98},[],{"trials":2817,"activeCount":98},[2818],{"nctId":2679,"briefTitle":2680,"status":1071,"phases":2819,"primaryCompletion":1193,"completion":2627,"start":2534,"enrollment":344,"conditions":2820,"interventions":2821},[90],[2124],[2660,2684],{"intervention":2823,"totalTrials":94,"cells":2824},"Vitamin D2 + vitamin D3",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"trials":2836,"activeCount":98},[2837],{"nctId":2838,"briefTitle":2839,"status":2645,"phases":2840,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":797,"conditions":2844,"interventions":2847},"NCT02054975","Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial",[90],"2015-09","2016-01","2014-01",[2845,2846],"Asthma","Vitamin D Deficiency",[2823,2848],"Vitamin D3",{"intervention":2848,"totalTrials":94,"cells":2850},{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"trials":2858,"activeCount":98},[],{"trials":2860,"activeCount":98},[],{"trials":2862,"activeCount":98},[2863],{"nctId":2838,"briefTitle":2839,"status":2645,"phases":2864,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":797,"conditions":2865,"interventions":2866},[90],[2845,2846],[2823,2848],{"intervention":2868,"totalTrials":94,"cells":2869},"Vitamin D",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2876,"PHASE4":2878,"NA":2880},{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[],{"trials":2879,"activeCount":98},[],{"trials":2881,"activeCount":98},[2882],{"nctId":2883,"briefTitle":2884,"status":1071,"phases":2885,"primaryCompletion":2753,"completion":2753,"start":2264,"enrollment":751,"conditions":2886,"interventions":2888},"NCT01724190","Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes",[90],[2887],"Type 1 Diabetes",[2868],{"intervention":2890,"totalTrials":94,"cells":2891},"Amoxicillin",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2893,"activeCount":98},[],{"trials":2895,"activeCount":98},[],{"trials":2897,"activeCount":98},[],{"trials":2899,"activeCount":98},[],{"trials":2901,"activeCount":98},[],{"trials":2903,"activeCount":98},[2904],{"nctId":2905,"briefTitle":2906,"status":1071,"phases":2907,"primaryCompletion":2908,"completion":2908,"start":2534,"enrollment":2909,"conditions":2910,"interventions":2912},"NCT01530009","The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children",[90],"2022-01",33,[2911],"Functional Gastrointestinal Disorders",[2890],{"intervention":2914,"totalTrials":94,"cells":2915},"Losartan",{"EARLY_PHASE1":2916,"PHASE1":2918,"PHASE2":2920,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2917,"activeCount":98},[],{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"trials":2925,"activeCount":98},[],{"trials":2927,"activeCount":98},[2928],{"nctId":2929,"briefTitle":2930,"status":1071,"phases":2931,"primaryCompletion":1501,"completion":2121,"start":2395,"enrollment":2932,"conditions":2933,"interventions":2936},"NCT01982695","Cardiomyopathy in DMD: Lisinopril vs. Losartan",[90],23,[2934,2935],"Duchenne Muscular Dystrophy (DMD)","Cardiomyopathy",[2914,2937],"Lisinopril",{"intervention":2937,"totalTrials":94,"cells":2939},{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2941,"activeCount":98},[],{"trials":2943,"activeCount":98},[],{"trials":2945,"activeCount":98},[],{"trials":2947,"activeCount":98},[],{"trials":2949,"activeCount":98},[],{"trials":2951,"activeCount":98},[2952],{"nctId":2929,"briefTitle":2930,"status":1071,"phases":2953,"primaryCompletion":1501,"completion":2121,"start":2395,"enrollment":2932,"conditions":2954,"interventions":2955},[90],[2934,2935],[2914,2937],{"intervention":2957,"totalTrials":94,"cells":2958},"Intravenous opioids",{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2963,"PHASE3":2965,"PHASE4":2967,"NA":2969},{"trials":2960,"activeCount":98},[],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[],{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[2971],{"nctId":2972,"briefTitle":2973,"status":1071,"phases":2974,"primaryCompletion":1865,"completion":1865,"start":2975,"enrollment":2976,"conditions":2977,"interventions":2978},"NCT01293136","Retrospective Femoral Nerve Block Study",[],"2011-02",400,[1224],[2957]]